BioStock: BioInvent reports promising response rate in ovarian cancer
BioInvent International recently announced promising interim results from one of its ongoing Phase IIa trials. The data shows that the company's lead drug candidate, BI-1808, in combination with Keytruda, achieved an overall response rate of 24 per cent in heavily pre-treated ovarian cancer patients – a result that stands out in a patient group with few effective treatment options. To learn more, BioStock turned to CEO Martin Welschof for a comment.
Read the full article at biostock.se:
https://biostock.se/en/2026/01/bioinvent-rapporterar-lovande-respons-vid-aggstockscancer/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se